about
Planar fluorescence imaging using normalized data.Outcomes and patterns of care in adult skull base chordomas from the Surveillance, Epidemiology, and End Results (SEER) database.Analysis of patient outcomes following proton radiation therapy for retinoblastoma.Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases.Volumetric tomography of fluorescent proteins through small animals in vivo.Approximating convex pareto surfaces in multiobjective radiotherapy planning.Proton radiation therapy for the treatment of retinoblastoma.Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastasesMapping (15)O production rate for proton therapy verificationSummary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastasesDeep sequencing identifies IDH1 R132S mutation in adult medulloblastoma.Patient study of in vivo verification of beam delivery and range, using positron emission tomography and computed tomography imaging after proton therapy.Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib.Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological gradeUnilateral Eye Findings: A Rare Herald of Acute Leukemia.Spatiotemporal Fractionation Schemes for Irradiating Large Cerebral Arteriovenous Malformations.Radiation therapy in acromegaly.Feasibility of Using Distal Endpoints for In-room PET Range Verification of Proton Therapy.Late effects of CNS radiation therapy.Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy.Turner syndrome and meningioma: support for a possible increased risk of neoplasia in Turner syndrome.Outcomes of proton therapy for the treatment of uveal metastases.Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes.Visual Outcomes after Proton Beam Irradiation for Choroidal Melanomas Involving the Fovea.The role of radiotherapy in the management of high-grade meningiomas.Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA).Practice Patterns Analysis of Ocular Proton Therapy Centers: The International OPTIC Survey.Evolution of cerebral microbleeds after cranial irradiation in medulloblastoma patients.Management of GBM: a problem of local recurrence.Outcomes after whole brain reirradiation in patients with brain metastases.Planned two-fraction proton beam stereotactic radiosurgery for high-risk inoperable cerebral arteriovenous malformations.Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients.Analysis of After-Hours Patient Telephone Calls in Two Academic Radiation Oncology Departments: An Opportunity for Improvement in Patient Safety and Quality of Care.The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases.Molecular analysis of episomal human papillomavirus type 16 DNA in a cervical carcinoma cell line.The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer.Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.Multicriteria plan optimization in the hands of physicians: a pilot study in prostate cancer and brain tumors.The impact of different stereotactic radiation therapy regimens for brain metastases on local control and toxicity.
P50
Q31029609-7FFF1E3C-929E-4D95-93BA-74DBCCFF0D70Q33275268-7E1AA420-0A1E-40F9-927F-4BC833DC1360Q33782262-624FA8B4-A067-4820-8FFD-85BC2C81BEA2Q33874796-E90B00CC-1796-4FD7-8047-CF23C6A27DBEQ34234430-327D5AEB-7657-4DE4-ACAE-AAD0268259A1Q34571714-5D8E6F80-7078-42BB-ABD3-808A3A13B956Q34617231-2B5A1F69-94E4-4EF9-8B4D-964C9250C8F6Q34886787-63FF33A7-AB5C-4EE3-983C-AD2ABBFBE7EAQ35606975-7580C715-7EC6-4157-BAA8-F4A6883194EFQ35721137-3C9205F3-BC6C-4D5B-88D2-A34EC9A8C1ABQ35896018-B0599D03-225D-47DD-9C91-36B02D7E6AD2Q36102047-65ECC18A-0402-4DA6-944D-07A909862EE6Q36550838-C1EC76AA-2121-42DC-A86A-D94063263842Q36893234-9E4B3984-6E77-4512-97D3-FE950A030FEBQ36938401-C20252A1-D830-4728-8444-DA00E60A978CQ37008966-39DE1890-6CC3-49B9-97B2-69A2A911FCD0Q37032360-590A8E0D-86C0-4CF9-9280-561D4C43C279Q37509210-4F544236-EF59-42BB-9CDA-213BFD8B662FQ37615963-01FDA0BA-1686-4B4D-928F-D96B27BCE4E3Q37646416-7F5FDE42-3FF8-4700-8C1C-294A24E5B7FCQ38199901-E5F85D3D-6075-4F19-A273-50D7BC9D9F8AQ38274194-CDA8A1CA-485F-43F2-8A02-22BFD6A0081CQ38566832-8906C946-41A8-4DCF-A150-0AD7D4A2DF41Q38627186-B6F14AB4-D780-4F74-9328-AC50F39E66B1Q38652345-10B18367-98A8-4AEB-BF24-F034B05A24FFQ38790010-814D6B2A-400F-4B88-AEF7-F07C56363DF2Q38880419-738DD3B5-4560-4EA8-AB36-784AE682AFC5Q38999000-00C390FF-4D9B-4D8C-82C5-330A2D5DC326Q39220867-9D28ECE9-A5B9-4D84-B542-1188EF5B7CD3Q39265253-AF2D98D5-3933-4F84-B83B-D9B696A5F0E9Q39685248-90BB7E65-380D-42E2-B2E7-4BF8B332C745Q39925540-FF1558EB-ABE9-4FD8-9448-3E9180EA50EBQ39975138-65C13A59-25D7-40E8-93CB-A63C4522D705Q40117357-4058D939-469F-4A8B-BD7B-EE79859C9EF8Q40593422-BEB7E449-A98B-48ED-A322-663B289277C8Q41060165-FCB69605-33FA-4E5F-96F0-C4FF256C660DQ42435160-0C2F5F7F-96C9-4259-879B-505544A3445CQ42702324-00984E3A-8972-4AA9-B318-1DE60445AD2BQ43290201-2CE34A9D-CED9-4C18-BD87-055257745326Q43379630-A792DBCA-836D-46CD-8E02-9A6EC37B6973
P50
description
researcher ORCID ID = 0000-0003-1550-9726
@en
name
Helen A Shih
@ast
Helen A Shih
@en
Helen A Shih
@es
Helen A Shih
@nl
type
label
Helen A Shih
@ast
Helen A Shih
@en
Helen A Shih
@es
Helen A Shih
@nl
prefLabel
Helen A Shih
@ast
Helen A Shih
@en
Helen A Shih
@es
Helen A Shih
@nl
P1153
7201982541
P31
P496
0000-0003-1550-9726